Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

How to overcome resistance of influenza A viruses against adamantane derivatives

Identifieur interne : 001B78 ( Main/Merge ); précédent : 001B77; suivant : 001B79

How to overcome resistance of influenza A viruses against adamantane derivatives

Auteurs : C. Scholtissek [États-Unis] ; G. Quack [Allemagne] ; H. D. Klenk [Allemagne] ; R. G. Webster [États-Unis]

Source :

RBID : Pascal:98-0232689

Descripteurs français

English descriptors

Abstract

We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:98-0232689

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">How to overcome resistance of influenza A viruses against adamantane derivatives</title>
<author>
<name sortKey="Scholtissek, C" sort="Scholtissek, C" uniqKey="Scholtissek C" first="C." last="Scholtissek">C. Scholtissek</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Quack, G" sort="Quack, G" uniqKey="Quack G" first="G." last="Quack">G. Quack</name>
<affiliation wicri:level="3">
<inist:fA14 i1="02">
<s1>Merz, GmbH, Eckenheimer Landstrasse 100-104</s1>
<s2>60318 Frankfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Klenk, H D" sort="Klenk, H D" uniqKey="Klenk H" first="H. D." last="Klenk">H. D. Klenk</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17</s1>
<s2>35037 Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Webster, R G" sort="Webster, R G" uniqKey="Webster R" first="R. G." last="Webster">R. G. Webster</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">98-0232689</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0232689 INIST</idno>
<idno type="RBID">Pascal:98-0232689</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000081</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000133</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000080</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000080</idno>
<idno type="wicri:doubleKey">0166-3542:1998:Scholtissek C:how:to:overcome</idno>
<idno type="wicri:Area/Main/Merge">001B78</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">How to overcome resistance of influenza A viruses against adamantane derivatives</title>
<author>
<name sortKey="Scholtissek, C" sort="Scholtissek, C" uniqKey="Scholtissek C" first="C." last="Scholtissek">C. Scholtissek</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Quack, G" sort="Quack, G" uniqKey="Quack G" first="G." last="Quack">G. Quack</name>
<affiliation wicri:level="3">
<inist:fA14 i1="02">
<s1>Merz, GmbH, Eckenheimer Landstrasse 100-104</s1>
<s2>60318 Frankfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Klenk, H D" sort="Klenk, H D" uniqKey="Klenk H" first="H. D." last="Klenk">H. D. Klenk</name>
<affiliation wicri:level="3">
<inist:fA14 i1="03">
<s1>Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17</s1>
<s2>35037 Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Giessen</region>
<settlement type="city">Marbourg</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Webster, R G" sort="Webster, R G" uniqKey="Webster R" first="R. G." last="Webster">R. G. Webster</name>
<affiliation wicri:level="2">
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">Tennessee</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amantadine</term>
<term>Antiviral</term>
<term>Hemagglutinin</term>
<term>Influenzavirus A</term>
<term>Ionic channel</term>
<term>Memantine</term>
<term>Resistance</term>
<term>Reversion</term>
<term>Structure activity relation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Influenzavirus A</term>
<term>Antiviral</term>
<term>Résistance</term>
<term>Amantadine</term>
<term>Mémantine</term>
<term>Canal ionique</term>
<term>Hémagglutinine</term>
<term>Relation structure activité</term>
<term>Réversion</term>
<term>Protéine M2</term>
<term>Adamantane dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>États-Unis</li>
</country>
<region>
<li>District de Darmstadt</li>
<li>District de Giessen</li>
<li>Hesse (Land)</li>
<li>Tennessee</li>
</region>
<settlement>
<li>Francfort-sur-le-Main</li>
<li>Marbourg</li>
</settlement>
</list>
<tree>
<country name="États-Unis">
<region name="Tennessee">
<name sortKey="Scholtissek, C" sort="Scholtissek, C" uniqKey="Scholtissek C" first="C." last="Scholtissek">C. Scholtissek</name>
</region>
<name sortKey="Webster, R G" sort="Webster, R G" uniqKey="Webster R" first="R. G." last="Webster">R. G. Webster</name>
</country>
<country name="Allemagne">
<region name="Hesse (Land)">
<name sortKey="Quack, G" sort="Quack, G" uniqKey="Quack G" first="G." last="Quack">G. Quack</name>
</region>
<name sortKey="Klenk, H D" sort="Klenk, H D" uniqKey="Klenk H" first="H. D." last="Klenk">H. D. Klenk</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B78 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001B78 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:98-0232689
   |texte=   How to overcome resistance of influenza A viruses against adamantane derivatives
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021